@chasvitalityrx's enclomiphene protocol claims, fact-checked

What did @chasvitalityrx actually say?

The creator argued that enclomiphene's bad reputation comes entirely from people dosing it daily, "like it's a damn multivitamin." The fix, they claim, is intermittent dosing every other day or three to four times per week, combined with DHEA, low-dose progesterone, and supportive nutrients. They assert that daily dosing "blocks the estrogen receptors in the brain 24-7, which tanks your growth hormone, ruins your mood, and ironically kills your libido." The implied promise: get the protocol right and testosterone rises, mood stabilizes, libido returns, and growth hormone doesn't crash. They also frame all critics as users who simply misapplied the drug, not as people who had legitimate clinical experiences or who are reporting documented adverse events.

Does the science back this up?

Partially, but with significant gaps. The receptor recovery logic has some biological plausibility, but there are no published randomized controlled trials specifically comparing daily versus intermittent enclomiphene dosing on growth hormone or libido outcomes. That matters a lot.

Enclomiphene is the trans-isomer of clomiphene and acts as a selective estrogen receptor modulator (SERM) at the hypothalamic level, stimulating LH and FSH release. Wiehle et al. (2014, Therapeutic Advances in Urology) showed enclomiphene raised testosterone and gonadotropins in hypogonadal men with fewer estrogenic side effects than testosterone replacement, which is a real and meaningful finding. Kaminetsky et al. (2013, Journal of Sexual Medicine) confirmed it preserved spermatogenesis, unlike exogenous testosterone.

However, the specific claim that daily dosing "tanks growth hormone" is not well-supported by peer-reviewed data. The studies on clomiphene and growth hormone are limited and conflicting. Vision disturbances, including the blurred vision the caption references, are a documented class effect of SERMs and are not simply a dosing-frequency artifact. The FDA cited visual side effects as a concern during enclomiphene's new drug application review, and that concern doesn't disappear with an alternate-day schedule.

What did they get wrong (or right)?

Credit where it's due: the core pharmacology isn't wrong. Enclomiphene does work upstream, stimulating the HPG axis rather than suppressing it. That distinction from exogenous testosterone is real and clinically meaningful for men who want to preserve fertility. The idea that receptor dynamics matter for SERM protocols also isn't invented, it's a reasonable extrapolation from tamoxifen and clomiphene literature.

But several claims are either overconfident or unsupported:

• The growth hormone claim is the weakest part. There is no solid clinical evidence that daily enclomiphene specifically suppresses GH in humans at typical therapeutic doses. This appears to be extrapolated from general estrogen receptor biology or gym-community lore, not from trials.
• Framing all critics as people who "used it like a caveman" is rhetorically convenient but factually dishonest. Adverse event reports exist in the literature independent of dosing frequency.
• The DHEA and progesterone stack is presented as a logical system without citing any evidence that this combination improves outcomes. Adding compounds to a protocol isn't optimization by default; it's additional variables with additional risks.
• Vision problems are not purely a dosing-frequency issue. They are a known SERM class effect.

What should you actually know?

Enclomiphene is a legitimate investigational and off-label tool for secondary hypogonadism, particularly for men where fertility preservation matters. The evidence base, while growing, is still thin compared to testosterone replacement therapy. Wiehle et al. (2014) and Surampudi et al. (2014, Current Medical Research and Opinion) provide reasonable support for its use in specific populations, but neither study defines an optimal dosing frequency for minimizing side effects.

If you are considering enclomiphene, the questions worth asking your provider are: What is your baseline LH and FSH? Has secondary hypogonadism been confirmed? What monitoring plan exists for estrogen, hematocrit, and vision changes? A protocol is only as good as the diagnostic workup behind it. The "F1 pit crew" framing sounds compelling, but no racing team skips the pre-race diagnostics.

The add-on compounds, specifically DHEA and progesterone, require their own clinical justification. Neither has established evidence supporting routine co-administration with enclomiphene in published trials. Treat any stack presented as a package deal with skepticism proportional to the evidence gap.